BXM Wealth LLC bought a new stake in Novartis AG (NYSE:NVS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 5,005 shares of the company's stock, valued at approximately $487,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Foundations Investment Advisors LLC grew its holdings in shares of Novartis by 26.9% in the fourth quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company's stock valued at $8,668,000 after purchasing an additional 18,894 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Novartis by 115.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company's stock worth $26,797,000 after purchasing an additional 124,111 shares during the period. CWA Asset Management Group LLC grew its stake in Novartis by 20.1% in the 4th quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company's stock valued at $3,001,000 after acquiring an additional 5,164 shares during the last quarter. Quantbot Technologies LP boosted its stake in shares of Novartis by 135.5% during the 3rd quarter. Quantbot Technologies LP now owns 39,976 shares of the company's stock worth $4,598,000 after purchasing an additional 22,998 shares during the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new stake in shares of Novartis during the 4th quarter worth about $239,000. 13.12% of the stock is owned by hedge funds and other institutional investors.
Novartis Stock Up 0.4 %
Novartis stock traded up $0.45 during mid-day trading on Wednesday, reaching $107.06. The company's stock had a trading volume of 1,255,358 shares, compared to its average volume of 1,944,202. The company has a market capitalization of $218.82 billion, a price-to-earnings ratio of 18.21, a price-to-earnings-growth ratio of 1.68 and a beta of 0.58. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The business's 50 day simple moving average is $100.91 and its 200 day simple moving average is $108.16. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04.
Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.98 EPS for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. As a group, research analysts anticipate that Novartis AG will post 8.44 earnings per share for the current year.
Analyst Ratings Changes
A number of analysts have recently issued reports on the stock. Erste Group Bank reiterated a "hold" rating on shares of Novartis in a research note on Tuesday, November 19th. HSBC cut shares of Novartis from a "hold" rating to a "reduce" rating in a report on Wednesday, December 4th. StockNews.com upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. BMO Capital Markets raised their price target on shares of Novartis from $118.00 to $120.00 and gave the company a "market perform" rating in a report on Wednesday, October 30th. Finally, UBS Group restated a "neutral" rating on shares of Novartis in a research report on Thursday, February 13th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $123.38.
Get Our Latest Stock Analysis on Novartis
Novartis Profile
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Stories
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
